Abstract
Background According to the World Health Organization, mental illness is one of the leading causes of disability worldwide. The first onset of mental illness usually occurs during childhood or adolescence, with nearly 12 million diagnosed cases in the United States alone. Neuroimaging and genetic testing have been invaluable in research on behavioral, affective, and attentional disorders, particularly with their potential predictive capabilities, and ability to improve diagnosis and to decrease the associated burdens of disease. The present study focused specifically the perspectives of mental health providers on the role of neuroimaging and genetic testing in clinical practice with children and adolescents. Methods We interviewed 38 psychiatrists, psychologists, and allied mental health professionals who work primarily with youth about their receptivity toward either the use of neuroimaging or genetic testing . Interviews probed the role they foresee for these modalities for prediction, diagnosis, treatment planning, and the benefits and risks they anticipate. Results Practitioners anticipated three major benefits associated with clinical introduction of imaging and genetic testing in the mental health care for youth: (1) improved understanding of the brain and mental illness, (2) more accurate diagnosis than available through conventional clinical examination, and (3) legitimization of treatment plans. They also perceived three major risks: (1) misuse or misinterpretation of the imaging or genetic data, (2) potential adverse impacts on employment and insurance as adolescents reach adulthood, and (3) infringements on self-esteem or self-motivation. Limitations The nature of the interview questions focused on the future of neuroimaging and genetic testing research in the context of clinical neuroscience. Therefore, the responses from interview participants are based on anticipated rather than actual experience. Conclusions Continued expansion of brain imaging and genetic testing into clinical care will require a delicate balance of brain biology and respect for autonomy in the still-evolving cognitive and affective world of young individuals.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adam D (2013) On the spectrum. Nature 496:416–418
Anderson J, Illes J (2012) Neuroimaging and mental health: drowning in a sea of acrimony. AJOB Neurosci 3:42–43. doi:10.1038/mp.2012.105.October
Austin JC, Honer WG (2005) The potential impact of genetic counseling for mental illness. Clin Genet 67:134–142. doi:10.1111/j.1399-0004.2004.00330.x
Austin JC, Honer WG (2007) The genomic era and serious mental illness: a potential application for psychiatric genetic counseling. Psychiatr Serv 58:254–261. doi:10.1176/appi.ps.58.2.254
Bloom D, Cafiero E, Jané-Llopis E et al (2011) The global economic burden of noncommunicable diseases. World Economic Forum and the Harvard School of Public Health, Cologny/Geneva, Switzerland
Boeije H (2002) A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant 36:391–409
Borgelt E, Buchman DZ, Illes J (2012a) Practitioners’ views on neuroimaging: mental health, patient consent, and choice. In: Richmond S, Rees G, Edwards S (eds) I know what you’re thinking: brain imaging and mental privacy. Oxford University Press, Oxford, pp 99–110
Borgelt EL, Buchman DZ, Illes J (2012b) Neuroimaging in mental health care: voices in translation. Front Hum Neurosci 6:1–5. doi:10.3389/fnhum.2012.00293
Borgelt EL, Buchman DZ, Illes J (2011) “This is why you’ve been suffering”: reflections of providers on neuroimaging in mental health care. J Bioeth Inq 8:15–25
Borgelt EL, Buchman DZ, Weiss M, Illes J (2012c) In search of “anything that would help”: parent perspectives on emerging neurotechnologies. J Atten Disord 1–7. doi:10.1177/1087054712445781
Buchman DZ, Borgelt EL, Whiteley L, Illes J (2012) Neurobiological narratives: Experiences of mood disorder through the lens of neuroimaging. Sociol Health Illn 35:66–81. doi:10.1111/j.1467-9566.2012.01478.x
Chubb JE, Bradshaw NJ, Soares DC et al (2008) The DISC locus in psychiatric illness. Mol Psychiatry 13:36–64. doi:10.1038/sj.mp.4002106
Collins P, Patel V, Joestl S et al (2011) Grand challenges in global mental health. Nature 475:27–30
Creswell J (2013) Qualitative inquiry and research design: choosing among five approaches (3rd ed.). Sage, Thousand Oaks, p 472
DeLisi LE, Bertisch H (2006) A preliminary comparison of the hopes of researchers, clinicians, and families for the future ethical use of genetic findings on schizophrenia. Am J Med Genet B Neuropsychiatr Genet 141B:110–115. doi:10.1002/ajmg.b.30249
Dumit J (2004) Picturing personhood: brain scans and biomedical identity. Princeton University Press, Princeton
Farah MJ, Gillihan SJ (2012) The puzzle of neuroimaging and psychiatric diagnosis: technology and nosology in an evolving discipline. AJOB Neurosci 3:31–41. doi:10.1080/21507740.2012.713072
Frances A (2009) A warning sign on the radio to DSM-V: beware of its unintended consequences. Psychiatric Times. Available at: http://www.psychiatrictimes.com/articles/warning-sign-road-dsm-v-beware-its-unintended-consequences?verify=0A. Accessed 26 June
Frances A (2013) DSM-5 writing mistakes will cause great confusion. Huffington Post. Available at: http://www.huffingtonpost.com/allen-frances/dsm5-writing-mistakes-wil_b_3419747.html. Accessed 11 June
Fu CHY, Costafreda SG (2013) Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift. Can J Psychiatr 58:499–508
Fusar-Poli P, Perez J, Broome M et al (2007) Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev 31:465–484. doi:10.1016/j.neubiorev.2006.11.006
Gillihan SJ, Parens E (2011) Should we expect “neural signatures” for DSM diagnoses? J Clin Psychiatry 72:1383–1389. doi:10.4088/JCP.10r06332gre
Gogtay N, Vyas NS, Testa R et al (2011) Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull 37:504–513. doi:10.1093/schbul/sbr030
Gore FM, Bloem PJN, Patton GC et al (2011) Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet 377:2093–2102. doi:10.1016/S0140-6736(11)60512-6
Huang J, Perlis R, Lee P et al (2010) Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry 167:1254–1263
Illes J, Lombera S, Rosenberg J, Arnow B (2008) In the mind’s eye: provider and patient attitudes on functional brain imaging. J Psychiatr Res 43:107–114. doi:10.1016/j.jpsychires.2008.02.008
Jabr F (2013) New DSV-5 ignores biology of mental illness. Scientific American, Mind and Brain. Available at: http://www.scientificamerican.com/article.cfm?id=new-dsm5-ignores-biology-mental-illness. Accessed 30 April
Jones I, Scourfield J, McCandless F, Craddock N (2002) Attitudes towards future testing for bipolar disorder susceptibility genes: a preliminary investigation. J Affect Disord 71:189–193
Kapur S, Phillips AG, Insel TR (2012) Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatr 17:1174–1179. doi:10.1038/mp.2012.105
Kemp AH, Gordon E, Rush AJ, Williams LM (2008) Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 13:1066–1086 (quiz 1087–1088)
Kieling C, Baker-Henningham H, Belfer M et al (2011) Child and adolescent mental health worldwide: evidence for action. Lancet 378:1515–1525. doi:10.1016/S0140-6736(11)60827-1
Kvaale EP, Haslam N, Gottdiener WH (2013) The “side effects” of medicalization: a meta-analytic review of how biogenetic explanations affect stigma. Clin Psychol Rev 33:782–794. doi:10.1016/j.cpr.2013.06.002
Kvale S (2006) Dominance through interviews and dialogues. Qual Inq 12:480–500. doi:10.1177/1077800406286235
Laegsgaard MM, Kristensen AS, Mors O (2009) Potential consumers’ attitudes toward psychiatric genetic research and testing and factors influencing their intentions to test. Genet Test Mol Biomarkers 13:57–65. doi:10.1089/gtmb.2008.0022
Lebowitz MS, Ahn W-K, Nolen-Hoeksema S (2013) Fixable or fate? Perceptions of the biology of depression. J Consult Clin Psychol 81:518–527. doi:10.1037/a0031730
Linden DEJ, Fallgatter AJ (2009) Neuroimaging in psychiatry: from bench to bedside. Front Hum Neurosci 3:1–7. doi:10.3389/neuro.09.049.2009
Linden DEJ, Habes I, Johnston SJ et al (2012) Real-time self-regulation of emotion networks in patients with depression. PLoS One 7:e38115. doi:10.1371/journal.pone.0038115
Mack N, Woodsong C, MacQueen K et al (2005) Qualitative research methods: a data collector’s field guide. Family Health International, Research Triangle Park, North Carolina
Meiser B, Kasparian NA, Mitchell PB et al (2008) Attitudes to genetic testing in families with multiple cases of bipolar disorder. Genet Test 12:233–244
Meiser B, Mitchell PB, McGirr H et al (2005) Implications of genetic risk information in families with a high density of bipolar disorder: An exploratory study. Soc Sci Med 60:109–118. doi:10.1016/j.socscimed.2004.04.016
Meyer-Lindenberg A, Weinberger DR (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7:818–827. doi:10.1038/nrn1993
Miguel-Hidalgo J (2013) Brain structural and functional changes in adolescents with psychiatric disorders. Int J Adolesc Med Health 25:245–256. doi:10.1515/ijamh-2013-0058.BRAIN
Onwuegbuzie AJ, Leech NL (2007) A call for qualitative power analyses. Qual Quant 41:105–121. doi:10.1007/s11135-005-1098-1
Owen MJ, Craddock N, Jablensky A (2007) The genetic deconstruction of psychosis. Schizophr Bull 33:905–911. doi:10.1093/schbul/sbm053
Pantelis C, Velakoulis D, Wood SJ et al (2007) Neuroimaging and emerging psychotic disorders: The Melbourne ultra-high risk studies. Int Rev Psychiatry 19:371–381. doi:10.1080/09540260701512079
Paus T, Keshavan M, Giedd JN (2008) Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 9:947–957. doi:10.1038/nrn2513
Pescosolido BA, Perry BL, Martin JK et al (2007) Stigmatizing attitudes and beliefs about treatment and psychiatric medications for children with mental illness. Psychiatr Serv 58:613–618. doi:10.1176/appi.ps.58.5.613
Pezawas L, Meyer-Lindenberg A (2010) Imaging genetics: progressing by leaps and bounds. Neuroimage 53:801–803. doi:10.1016/j.neuroimage.2010.08.001
Phelan JC (2005) Geneticization of deviant behavior and consequences for stigma: the case of mental illness. J Health Soc Behav 46:307–322. doi:10.1177/002214650504600401
Phillips ML (2012) Neuroimaging in psychiatry: bringing neuroscience into clinical practice. Br J Psychiatry J Ment Sci 201:1–3. doi:10.1192/bjp.bp.112.109587
Racine E, Bell E, Di Pietro NC et al (2011) Evidence-based neuroethics for neurodevelopmental disorders. Semin Pediatr Neurol 18:21–25. doi:10.1016/j.spen.2011.02.002
Raingruber B (2002) Client and provider perspectives regarding the stigma of and nonstigmatizing interventions for depression. Arch Psychiatr Nurs 16:201–207. doi:10.1053/apnu.2002.36230
Rapoport JL, Gogtay N (2008) Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging. Neuropsychopharmacology 33:181–197. doi:10.1038/sj.npp.1301553
Singh I, Rose N (2009) Biomarkers in psychiatry. Nature 460:202–207. doi:10.1038/460202a
Smith L, Sapers B, Reus V, Freimer N (1996) Attitudes towards bipolar disorder and predictive genetic testing among patients and providers. J Med Genet 33:544–549
Tairyan K, Illes J (2009) Imaging genetics and the power of combined technologies: a perspective from neuroethics. Neuroscience 164:7–15. doi:10.1016/j.neuroscience.2009.01.052
Terry J, Lopez-Larson M, Frazier JA (2009) Magnetic resonance imaging studies in early onset bipolar disorder: An updated review. Child Adolesc Psychiatr Clin N Am 18:421–439. doi:10.1016/j.chc.2008.12.004
Trippitelli CL, Jamison KR, Folstein MF et al (1998) Pilot study on patients’ and spouses’ attitudes toward potential genetic testing for bipolar disorder. Am J Psychiatr 155:899–904
Velakoulis D, Wood SJ, Wong MT et al (2006) Hippocampal and amygdala volumes according to psychosis stage and diagnosis. Arch Gen Psychiatr 63:139–149
Wertz DC, Fanos JH, Reilly PR (1994) Genetic testing for children and adolescents. Who decides? JAMA 272:875–881
Wood SJ, Reniers RLEP, Heinze K (2013) Neuroimaging findings in the at-risk mental state: a review of recent literature. Can J Psychiatry 58:13–18
Wrigley S, Jackson H, Judd F, Komiti A (2005) Role of stigma and attitudes toward help-seeking from a general practitioner for mental health problems in a rural town. Aust N Z J Psychiatry 39:514–521. doi:10.1111/j.1440-1614.2005.01612.x
Yung A, Yuen H, Philips L, et al (2003) Mapping the onset of psychosis: the comprehensive assessment of at risk mental states (CAARMS). Int Congr Schizophr Res 2003
Yung AR, Yuen HP, McGorry PD et al (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatr 39:964–971. doi:10.1111/j.1440-1614.2005.01714.x
Acknowledgments
We thank the interview participants for their time and contribution to this study.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lee, G., Mizgalewicz, A., Borgelt, E., Illes, J. (2014). Genetic Testing and Neuroimaging for Youth at Risk for Mental Illness: Trading off Benefit and Risk. In: Lee, G., Illes, J., Ohl, F. (eds) Ethical Issues in Behavioral Neuroscience. Current Topics in Behavioral Neurosciences, vol 19. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2014_335
Download citation
DOI: https://doi.org/10.1007/7854_2014_335
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-44865-6
Online ISBN: 978-3-662-44866-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)